Page 1

S.No. NATCO NATCO Pharma Limited Regd . Office : Natco House , Road No. 2 , Banjara Hills , Hyderabad , Telangana - 500 034 . Phone : + 91-40-2354 7532 , Website : www.natcopharma.co in , CIN : L24230TG1981PLC003201 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2021 Particulars 30 September 2021 Unaudited Quarter ended 30 June 2021 Unaudited ( in millions except per share data ) Half Year ended Year ended 30 September 2020 30 September 2021 30 September 2020 31 March 2021 Unaudited Unaudited Unaudited Audited Income 1 Revenue from operations ( refer note 4 ) 2 Other income 3 Total income ( 1 + 2 ) 3.772 4.103 8.022 7.875 13.656 380 4,152 170 4,273 257 8,279 550 8,425 444 14,100 20.521 1,036 21,557 4 Expenses Cost of materials consumed 1.156 1.099 866 2.255 2.080 3.729 Purchases of stock - in - trade 127 77 1.082 204 1,514 1.866 Changes in inventories of finished goods . ( 358 ) ( 385 ) ( 743 ) 144 ( 481 ) work - in - progress and stock - in - trade Employee benefits expense 1.092 1,081 1.237 2,173 2,189 4.149 Finance costs 40 20 27 60 64 133 Depreciation and amortisation expense 347 338 287 685 567 1.169 Other expenses 1.050 1,133 2.072 2.183 3,254 5.196 Total expenses 3,454 3.363 5.572 6,817 9,812 15,761 5 Profit before exceptional items and tax ( 3-4 ) 698 910 2,707 1,608 4,288 5,796 6 Exceptional items 7 Profit before tax ( 5-6 ) 698 910 2,707 1,608 4.288 5,796 8 Tax expense ( i ) Current tax ( ii ) Income - tax for earlier years ( iii ) Deferred tax ( credit ) / charge ( refer note 5 ) Total tax expense 9 Profit for the period / year ( 7-8 ) 161 156 718 317 1.143 1,408 - 70 ( 114 ) 4 ( 50 ) ( 110 ) ( 115 ) ( 106 ) 47 160 668 207 1,028 1,372 651 750 2,039 1,401 3,260 4,424 10 Other comprehensive income ( net of tax ) A. Items that will not be reclassified subsequently to profit or loss : Remeasurement of defined benefit plans ( 2 ) ( 2 ) ( 19 ) ( 4 ) ( 39 ) ( 8 ) Net ( losses ) / gains from investments in equity instruments designated at Fair value through other comprehensive income ( FVTOCI ) ( 24 ) 100 91 76 110 143 Income - tax relating to items that will not be reclassified to profit or loss 3 ( 10 ) ( 11 ) ( 7 ) ( 12 ) ( 10 ) ( 23 ) 88 61 65 59 125 B. Items that will be reclassified subsequently to profit or loss : Exchange differences on translation of foreign operations ( 45 ) ( 20 ) ( 106 ) ( 65 ) ( 83 ) ( 38 ) ( 45 ) ( 20 ) ( 106 ) ( 65 ) ( 83 ) ( 38 ) Total other comprehensive income ( net of tax ) ( A + B ) ( 68 ) 68 ( 45 ) ( 24 ) 87 11 Total comprehensive income for the period / year ( 9 + 10 ) 583 818 1,994 1,401 3,236 4,511 12 Profit for the period / year attributable to : Owners of the Company 651 750 2.024 1.401 3,252 Non - controlling interests 15 8 4.409 15 13 Other comprehensive income attributable to : Owners of the Company Non - controlling interests 14 Total comprehensive income attributable to : Owners of the Company Non - controlling interests ་ ཆེ ( 68 ) 68 ( 45 ) ( 24 ) 87 583 818 1.979 1,401 3.228 15 8 4.496 15 15 Paid - up equity share capital ( face value of 22 each ) 365 365 364 365 364 365 16 Other equity 40,851 17 Earnings per share ( face value 22 each ) Basic ( in ) Diluted ( in ) See accompanying notes to the consolidated financial results . 3.57 3.57 4.11 4.11 11.12 11.09 7.68 17.86 24.20 7.67 17.81 24.16 ( Non - annualised ) ( Non - annualised ) ( Non - annualised ) ( Non - annualised ) ( Non - annualised ) NATCO * Pharma HATCO Hyder *